Cargando…

Permanent (125)I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

PURPOSE: To evaluate predictive factors for PSA bounce after (125)I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. MATERIALS AND METHODS: Men treated with exclusive permanent (125)I seed brachytherapy from November 1999,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazeron, Renaud, Bajard, Agathe, Montbarbon, Xavier, Gassa, Frédéric, Malet, Claude, Rocher, François, Clippe, Sébastien, Bringeon, Gabriel, Desmettre, Olivier, Pommier, Pascal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342157/ https://www.ncbi.nlm.nih.gov/pubmed/22449081 http://dx.doi.org/10.1186/1748-717X-7-46

Ejemplares similares

Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival
por: Robin, Sophie, et al.
Publicado: (2021)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy
por: Yamamoto, Yoichiro, et al.
Publicado: (2016)

Clinical features of prostate-specific antigen bounce after (125)I brachytherapy for prostate cancer
por: Kubo, Katsumaro, et al.
Publicado: (2018)

Prostate-Specific Antigen Bounce after (125)I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer
por: Kim, Tae Hyung, et al.
Publicado: (2022)

Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer
por: Njomnang Soh, Patrice, et al.
Publicado: (2013)

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2020)

Re-implantation after insufficient primary 125-i permanent prostate brachytherapy
por: Putora, Paul Martin, et al.
Publicado: (2013)

Late seed migration after prostate brachytherapy with Iod-125 permanent implants
por: Maletzki, Philipp, et al.
Publicado: (2018)

Analysis of immune status after iodine-125 permanent brachytherapy in prostate cancer
por: Du, E, et al.
Publicado: (2017)

The phylogeny of permanent prostate brachytherapy
por: Aronowitz, Jesse N., et al.
Publicado: (2013)

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy
por: Hackett, Cian, et al.
Publicado: (2014)

Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
por: Galego, Pedro, et al.
Publicado: (2015)

Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis
por: Bernstein, Michael B., et al.
Publicado: (2013)

Correlations between intraplan and postplan parameters in I-125 permanent prostate brachytherapy using loose seeds or linked seeds
por: Ito, Fumitaka, et al.
Publicado: (2022)

Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus ‘X’
por: Ahmed, Kamran A, et al.
Publicado: (2014)

Benefits of a dual sagittal crystal transducer for ultrasound imaging during I-125 seed implantation for permanent prostate brachytherapy
por: Kaljouw, Emmie, et al.
Publicado: (2012)

PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up
por: Makarewicz, Roman, et al.
Publicado: (2009)

Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy
por: Makino, Tomoyuki, et al.
Publicado: (2016)

Comparison between preoperative and real-time intraoperative planning (125)I permanent prostate brachytherapy: long-term clinical biochemical outcome
por: Matzkin, Haim, et al.
Publicado: (2013)

Analysis of radioactive implant migration in patients treated with iodine-125 seeds for permanent prostate brachytherapy with MRI-classified median lobe hyperplasia
por: Muraki, Koichiro, et al.
Publicado: (2021)

Effect of constipation on dosimetry after permanent seed brachytherapy for prostate cancer
por: Otón, L. Fernando, et al.
Publicado: (2015)

A comparative evaluation of loading times and exposures for permanent prostate brachytherapy
por: Bice, W. S., et al.
Publicado: (2002)

Prostate-Specific Antigen Bounce Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Vu, Charles C., et al.
Publicado: (2014)

Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature
por: Kunogi, Hiroaki, et al.
Publicado: (2016)

Bioevaluation of (125)I Ocu-Prosta seeds for application in prostate cancer brachytherapy
por: Mukherjee, Archana, et al.
Publicado: (2014)

Risk factors for rectal bleeding associated with I-125 brachytherapy for prostate cancer
por: Harada, Kosaku, et al.
Publicado: (2012)

Prostate brachytherapy with iodine-125 seeds: analysis of a single institutional cohort
por: Leite, Elton Trigo Teixeira, et al.
Publicado: (2019)

Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA
por: Merrick, Gregory S., et al.
Publicado: (2017)

Low‐Dose‐Rate Prostate Brachytherapy (LDR‐PB) adopts postsurgical PSA value for definition of cure
por: Uribe, Jennifer, et al.
Publicado: (2020)

Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources
por: Commission Internationale de Protection contre les Radiations
Publicado: (2005)

Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation
por: Ruge, Maximilian I, et al.
Publicado: (2012)

Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas
por: Wang, Congxiao, et al.
Publicado: (2020)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2018)

Combined intra-cavitary and interstitial image-guided adaptative brachytherapy for cervical stump carcinomas: technical and clinical results of six patients
por: Guillemin, Florent, et al.
Publicado: (2022)

A simple technique for the generation of institution-specific nomograms for permanent prostate cancer brachytherapy
por: Lafata, Kyle J., et al.
Publicado: (2014)

A novel greedy heuristic‐based approach to intraoperative planning for permanent prostate brachytherapy
por: Liang, Bin, et al.
Publicado: (2015)

Correction to: Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas
por: Wang, Congxiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_92vk1qtr2ldea1arp2dj3anopu